Annexon Q2 2026: $55.3M Net Loss, Cash Runway Extended into 2028
ANNX has more than doubled off its 52-week low of $2.03.
Summary
Annexon's Q2 2026 10-Q confirms a $55.3M net loss, $209.2M in cash, and a cash runway extended into 2028. The filing also includes the charter amendment increasing authorized shares to 500 million.
Key Events · Earnings and Guidance · ANNX
-
Q2 Net Loss of $55.3M
For the three months ended June 30, 2026, the net loss widened to $55.3 million, or $0.28 per share, from $49.2 million, or $0.34 per share, in the prior-year period. A $6.0 million increase in contract manufacturing costs for vonaprument drove the larger loss.
-
Cash Runway Extended into 2028
Cash and short-term investments totaled $209.2 million as of June 30, 2026. Management now expects this to fund operating expenses into 2028, an improvement from the prior 'at least twelve months' guidance.
-
Authorized Shares Increased to 500M
The 10-Q includes the June 11, 2026 charter amendment increasing authorized common stock from 300 million to 500 million shares. This provides headroom for the $150 million ATM program and potential future equity financings.
-
ATM Program Utilization
During H1 2026, the company sold 5.7 million shares under the 2026 ATM program for net proceeds of $31.0 million, and 6.0 million shares under the 2024 ATM program for $32.7 million. Approximately $117.8 million remained available under the 2026 ATM as of June 30, 2026.
Analysis · ANNX · Life Sciences
A net loss of $55.3 million, or $0.28 per share, was reported for the second quarter, alongside $209.2 million in cash and short-term investments. Management now projects the cash runway extends into 2028, a meaningful improvement from the prior guidance of at least twelve months. The filing also formalizes the June 11, 2026 charter amendment increasing authorized shares from 300 million to 500 million, providing ample headroom for the $150 million ATM program and future financings. Two late-stage programs continue to advance: tanruprubart in GBS with an EMA MAA under review and a planned BLA submission in Q4 2026, and vonaprument in GA with the Phase 3 ARCHER II trial's Month 15 primary endpoint on track for Q4 2026.
At the time of this filing, ANNX was trading at $5.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $876.6M. The 52-week trading range was $2.03 to $7.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.